Frax in haemodialysis patients: preliminary results

The incidence of bone fractures is several times higher in haemodialysis (HD) patients than in the general population. FRAX is a fracture risk evaluation tool and shows a 10-year probability of bone fracture. The aim of this study was to evaluate the FRAX score in haemodialysis patients. The study included 214 HD patients (81 female). We used the following calculation tool: https://www.sheffield.ac.uk/FRAX/?lang=cr. Increased risk for major fracture (MF) was defined as FRAX > 20% and for hip fracture (HF) > 3%. If renal osteodystrophy (ROD) is defined as primary osteoporosis, the average FRAX value for MF is 7.4 +/- 6.4% and for HF 3.5 +/- 4.1%, and as secondary osteoporosis, the average FRAX value for MF is 10.3 +/- 8.4 %, for HF 5.4 +/- 5.9%. 13.6% of patients or 49.1% had an increased risk for MF or HF if ROD was defined as secondary osteoporosis. If it was defined as primary osteoporosis, the results were 7.1% for MF or 39.2% for HF. In women, FRAX values were significantly higher for both HF and MF. According to our preliminary results, a large number of patients have an increased FRAX score risk, especially if we define ROD as secondary osteoporosis. The FRAX score is higher in women.